Non-Coding RNA Networks in Pulmonary Arterial Hypertension

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Genetics

Background:

• Pulmonary artery hypertension (PAH) is a severe cardiovascular disease characterized by increased pulmonary artery pressure and resistance.
• Current PAH therapies are insufficient, focusing on vasodilation rather than reversing underlying vascular remodeling.
• Unmet clinical needs persist for effective PAH treatments, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review recent advancements in understanding the role of non-coding RNAs (ncRNAs) in PAH pathogenesis.
• To explore the potential of various ncRNAs, including lncRNAs, circRNAs, miRNAs, and piRNAs, in disease development.
• To discuss challenges and future directions for ncRNAs as biomarkers and therapeutic targets in PAH.

Main Methods:

• Literature review of recent scientific publications on ncRNAs and PAH.
• Analysis of the regulatory mechanisms of ncRNAs in pulmonary vascular remodeling.
• Synthesis of current knowledge on ncRNA expression and function in PAH.

Main Results:

• Non-coding RNAs (ncRNAs) play a critical role in the occurrence and development of PAH.
• Specific ncRNAs, such as long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), microRNAs (miRNAs), and PIWI-interacting RNAs (piRNAs), are implicated in PAH pathogenesis.
• These ncRNAs regulate PAH through mechanisms including chromatin modification, transcriptional regulation, and post-translational modifications.

Conclusions:

• NcRNAs represent a promising area for developing novel diagnostic biomarkers for PAH.
• Targeting ncRNAs offers a potential therapeutic strategy to address the unmet needs in PAH treatment.
• Further research into ncRNA functions and interactions is crucial for advancing PAH therapy.